Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DiaMedica Announces Positive Results in Top-Line Data From the Phase II ReMEDy Acute Ischemic Stroke Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Guggenheim Securities, LLC","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"DiaMedica Announces Closing of $23 Million Public Offering of Common Shares","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DiaMedica Therapeutics Hosting Key Opinion Leader Webinar on DM199 for Treatment of Acute Ischemic Stroke","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DiaMedica Therapeutics to Present Research at the National Kidney Foundation\u2019s 2021 Spring Clinical Meetings","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2\/3 AIS Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DiaMedica Therapeutics Announces Clinical Hold of its Phase 2\/3 ReMEDy2 Clinical Trial for DM199","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"No Remedy For Diamedica As FDA Maintains Hold On Stroke Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Craig-Hallum Capital Group LLC","pharmaFlowCategory":"D","amount":"$37.5 million","upfrontCash":"Undisclosed","newsHeadline":"DiaMedica Therapeutics Announces $37.5 Million Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DiaMedica Therapeutics Announces that the FDA has Removed the Clinical Hold on DM199 Phase 2\/3 Trial for Ischemic Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Craig-Hallum Capital Group LLC","pharmaFlowCategory":"D","amount":"$37.5 million","upfrontCash":"Undisclosed","newsHeadline":"DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by DiaMedica Therapeutics

    Menu

    DiaMedica Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              DiaMedica Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement

              Details:

              The Company intends to use the net proceeds to continue its clinical and product development activities for DM199 (recombinant human tissue kallikrein), including its pivotal Phase 2/3, ReMEDy2 clinical trial to treat acute ischemic stroke patients.

              Lead Product(s): Recombinant Human Tissue Kallikrein

              Therapeutic Area: Neurology Product Name: DM199

              Highest Development Status: Phase II/ Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Craig-Hallum Capital Group LLC

              Deal Size: $37.5 million Upfront Cash: Undisclosed

              Deal Type: Private Placement June 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DiaMedica Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DiaMedica Therapeutics Announces $37.5 Million Private Placement

              Details:

              The Company intends to use the net proceeds to continue its clinical and product development activities for DM199 (recombinant human tissue kallikrein), including its pivotal Phase 2/3, ReMEDy2 clinical trial to treat acute ischemic stroke patients.

              Lead Product(s): Recombinant Human Tissue Kallikrein

              Therapeutic Area: Neurology Product Name: DM199

              Highest Development Status: Phase II/ Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Craig-Hallum Capital Group LLC

              Deal Size: $37.5 million Upfront Cash: Undisclosed

              Deal Type: Private Placement June 21, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DiaMedica Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DiaMedica Therapeutics Announces that the FDA has Removed the Clinical Hold on DM199 Phase 2/3 Trial for Ischemic Stroke

              Details:

              DM199 is a recombinant human tissue kallikrein-1. KLK1 is a serine protease that plays an important role in the regulation of diverse physiological processes including blood flow, oxidative stress and neurogenesis, which is investigated for Ischemic Stroke.

              Lead Product(s): Recombinant Human Tissue Kallikrein

              Therapeutic Area: Neurology Product Name: DM199

              Highest Development Status: Phase II/ Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 21, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DiaMedica Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              No Remedy For Diamedica As FDA Maintains Hold On Stroke Trial

              Details:

              DM199 is a recombinant human tissue kallikrein-1. KLK1 is a serine protease that plays an important role in the regulation of diverse physiological processes including blood flow, inflammation, fibrosis, oxidative stress and neurogenesis.

              Lead Product(s): Recombinant Human Tissue Kallikrein

              Therapeutic Area: Neurology Product Name: DM199

              Highest Development Status: Phase II/ Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 26, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DiaMedica Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199

              Details:

              Clinical Hold has placed on DM199, a recombinant form of human tissue KLK1, based on submission of three serious adverse event reports to the FDA related to clinically significant, transient hypotension (low blood pressure) occurring shortly after initiation of IV dose.

              Lead Product(s): DM199

              Therapeutic Area: Neurology Product Name: DM199

              Highest Development Status: Phase II/ Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DiaMedica Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2/3 AIS Trial

              Details:

              In the study, 45 patients received placebo and 46 were treated with DM199. During the 90-day follow-up period, recurrent ischemic stroke occurred in 6 patients of the placebo arm versus none in the DM199 arm. Moreover, 4 of the recorded strokes in the placebo arm were fatal.

              Lead Product(s): DM199

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: DM199

              Highest Development Status: Phase II/ Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DiaMedica Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DiaMedica Therapeutics to Present Research at the National Kidney Foundation’s 2021 Spring Clinical Meetings

              Details:

              DiaMedica's presentation include an abstract on REDUX Study: A Multicenter Study of DM199 in Chronic Kidney Disease Stage II or III” patients and an abstract on Kallikrein Protein (KLK1) Levels in Patients with Chronic Kidney Disease and Normal Kidney Function.

              Lead Product(s): DM199

              Therapeutic Area: Nephrology Product Name: DM199

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 05, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DiaMedica Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DiaMedica Therapeutics Hosting Key Opinion Leader Webinar on DM199 for Treatment of Acute Ischemic Stroke

              Details:

              DM199 is a recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1). DiaMedica plans to submit an investigational new drug (IND) application to the FDA for the phase 2/3 study in the first quarter of 2021.

              Lead Product(s): DM199

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: DM199

              Highest Development Status: Phase II/ Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DiaMedica Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DiaMedica Announces Closing of $23 Million Public Offering of Common Shares

              Details:

              Net proceeds to be used in continuing clinical and product development activities, including the addition of a new cohort III to its REDUX study to be comprised of Type II diabetes mellitus patients with CKD, hypertension and albuminuria, and general corporate purposes.

              Lead Product(s): DM199

              Therapeutic Area: Immunology Product Name: DM199

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Guggenheim Securities, LLC

              Deal Size: $20.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering August 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DiaMedica Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DiaMedica Announces Positive Results in Top-Line Data From the Phase II ReMEDy Acute Ischemic Stroke Study

              Details:

              DM199 met primary safety and tolerability endpoints in ReMEDy study top-line data. There was also a demonstrated therapeutic effect in participants who received tissue plasminogen activator (tPA) prior to enrolment.

              Lead Product(s): DM199

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 13, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY